Surprisingly, upon further assessment of subgroups, 18F-FDG uptake was significantly higher in RA subjects using anti-TNF therapy compared with the RA, DMARD group (with comparable disease activity, CRP and ESR levels) and control subjects, (aortic TBRmax: RA, TNF inhibition 2.42 ± 0.54 p = 0.004 versus controls. This evidence concerns the gene CRP and rheumatoid arthritis.